查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1627724

全球处方药市场：预测（2025-2030）

Global Prescription Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 155 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球处方药市场规模预计将以 4.67% 的复合年增长率增长，从 2025 年的 12,680.08 亿美元增长到 2030年终的15,930.19 亿美元。

处方药比非处方药 (OTC) 更有效。因此，使用不当会导致严重的副作用。这些药物是根据医生的处方笺提供给顾客的。您可能已经注意到，医生处方笺记事本或大多数药房标誌上的 Rx 符号是医疗处方符号。全球药品支出的成长可能会对预测期内的市场成长产生重大影响。

关键驱动因素之一是特种药物的高成本和治疗可用性的扩大。罕见疾病的流行将在预测期内进一步提振市场。全球慢性病的增加将在预测期内进一步推动处方药销售。此外，全球癌症病例数的增加也推动了预测期内的市场扩张。

此外，世界老年人数量的增加大大提高了预测期内的市场成长前景。世界已开发地区，尤其是北美，预计将在处方药市场中占据主要份额。同时，由于需要治疗的人数众多，亚太地区被认为是成长最快的地区之一。此外，透过更好的医疗设施改善医疗基础设施的大量投资进一步为预测期内的市场成长提供了机会。

按类型划分，市场分为学名药、孤儿药和其他处方药。依应用划分，全球处方药市场分为糖尿病、肿瘤、心血管疾病、自体免疫疾病等。市场依分销管道分为院内药局、药局及零售药局及网路药局。

处方药市场驱动因素

  • 世界各地慢性病的增加

人们广泛观察到全世界慢性病盛行率显着增加。其主要原因是都市化的进步和不健康的居住环境的建立。此外，全球老年人口的增加导致与老龄化相关的疾病增加，进一步增加了慢性病的增加，并推动了预测期内的市场成长。阿兹海默症、心血管疾病、肥胖和糖尿病等疾病属于慢性病。例如，根据阿兹海默症国际组织 (ADI) 的数据，截至 2020 年，全球有超过 5,500 万人患有失智症。这一数字预计在 20 年内将增加近一倍，到 2030 年达到 7,800 万，到 2050 年将达到 1.39 亿。其中大部分在开发中国家有所增加。

此外，癌症发生率上升进一步推动了预测期内的市场成长。例如，根据国家医学图书馆的数据，2022 年印度的癌症发生率估计为 1,461,427 人。粗率是每百万人口 100.4 人。在印度，九分之一的人一生中会罹患癌症。肺癌和乳癌是男性和女性最常见的癌症。淋巴球白血病（男孩：29.2%，女孩：24.2%）是印度儿童（0-14 岁）最常见的癌症。与 2020 年相比，2025 年癌症发生率预计将增加 12.8%。

心血管疾病盛行率的增加进一步促进了处方药销售，推动了预测期内的市场成长。根据疾病预防控制中心的数据，由心臟和血管疾病组成的心血管疾病是全球死亡和残疾的第一大原因。这种疾病的主要危险因子包括高血压或高血压，预计全球整体每年将导致 1,000 万人死亡。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖关键和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业和其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中发现新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业/市场考量、商机评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、监管影响、新产品开发、竞争讯息

调查范围

  • 2022年至2030年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略和市场占有率分析
  • 区域收益成长和预测分析，包括细分市场和国家
  • 公司简介（主要是策略、产品、财务资讯、主要动态等）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章全球处方药市场分析：按类型

  • 介绍
  • 非专利的
  • 孤儿药
  • 其他的

第六章全球处方药市场分析：依应用分类

  • 介绍
  • 糖尿病
  • 瘤
  • 心血管疾病
  • 自体免疫疾病
  • 其他的

第七章全球处方药市场分析：按分销管道

  • 介绍
  • 医院药房
  • 药局和零售药局
  • 网路药房

第八章全球处方药市场分析：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 其他的
  • 中东/非洲
    • 阿拉伯聯合大公国
    • 以色列
    • 沙乌地阿拉伯
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 併购/协议/合作
  • 竞争对手仪表板

第十章 公司简介

  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Bayer AG
  • Gilead Sciences, Inc
  • Eli Lilly and Company
  • Allergan
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
简介目录
Product Code: KSI061613887

The global prescription drug market is estimated to augment at a CAGR of 4.67%, increasing from US$1,268.008 billion in 2025 to US$1,593.019 billion by the end of 2030.

Prescription drugs are more potent in comparison to over-the-counter (OTC) drugs. Hence, their inappropriate use may lead to serious side effects. These medicines are handed over to customers based on doctors' prescriptions. One might have noticed on the doctor's prescription notepads and signs in most pharmacies that the symbol Rx is the symbol for medical prescription. Growing global pharmaceutical spending will have a significant impact on fueling the market growth during the forecast period.

One of the main drivers is the high cost of specialty medicines and the growing use of medical treatments. The prevalence of rare disorders further propels the market during the forecast period. The increasing number of chronic diseases worldwide is further raising the sales of prescription drugs in the forecast period. The growing number of cancer incidences worldwide is also driving the market expansion during the forecast period.

Furthermore, the growing number of elderly individuals worldwide has significantly raised market growth prospects in the forecast period. The developed regions of the world, particularly North America, is projected to hold a significant share in the prescription drug market. On the other hand, the Asia-Pacific region is regarded as one of the fastest-growing, owing to the prevalence of a large population requiring treatment. In addition, significant investments in improving healthcare infrastructure with better health facilities are further providing an opportunity for the market to grow during the forecast period.

Based on type, the market is categorized as generics, orphan drugs, and other prescription drugs. By application, the global prescription drug market is segregated into diabetes, oncology, cardiovascular diseases, autoimmune diseases, and others. The market is segmented by distribution channel into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

Global Prescription Drugs Market Drivers

  • Rising incidences of chronic diseases worldwide

It has been observed on a wide scale that there is a significant rise in the global chronic disease burden. One of the major reasons includes growing urbanization and the adoption of unhealthy living conditions. Additionally, the growing geriatric population worldwide is contributing to the rise of age-associated diseases, further augmenting chronic disease growth and fueling the market growth in the forecast period. Diseases such as Alzheimer's disease, cardiovascular disease, obesity, and diabetes are some chronic diseases. For instance, according to Alzheimer's Disease International (ADI), there were over 55 million people worldwide who are living with dementia as of 2020. The number will almost double in 20 years, reaching 78 million in 2030 and 139 million in 2050. Much of the increase will be in developing countries.

The rising incidences of cancer are further providing an impetus, fueling the market growth in the forecast period. For instance, according to the National Library of Medicine, the estimated incidence of cancer cases in 2022 was 14,61,427 in India. With the crude rate, it was 100.4 cases per 1,00,000 population. In India, one in nine people develops cancer in their lifetime. In males and females, lung and breast cancers are most often found. Lymphoid leukemia (among boys: 29.2% and girls: 24.2%) was the most prevalent childhood (0-14 years) cancer site in India. The incidence of cancer cases is estimated to increase by 12.8 percent in 2025 compared to 2020.

The growing prevalence of cardiovascular diseases is further contributing to the sales of prescription drugs, fueling the market growth in the forecast period. As per the CDC, cardiovascular diseases, comprising disorders of the heart and blood vessels, are ranked as the number one cause of death and disability globally. The major risk factors for this disease include high blood pressure or hypertension, which are attributed to causing a predicted 10 million deaths globally every year.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Global Prescription Drugs market is segmented and analyzed as follows:

By Type

  • Generics
  • Orphan Drugs
  • Others

By Application

  • Diabetics
  • Oncology
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Drug Stores & Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY TYPE

  • 5.1. Introduction
  • 5.2. Generics
  • 5.3. Orphan Drugs
  • 5.4. Others

6. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Oncology
  • 6.4. Cardiovascular Diseases
  • 6.5. Autoimmune Diseases
  • 6.6. Others

7. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Drug Stores & Retail Pharmacy
  • 7.4. Online Pharmacy

8. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. United Arab Emirates
    • 8.5.2. Israel
    • 8.5.3. Saudi Arabia
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Novartis AG
  • 10.2. Pfizer Inc.
  • 10.3. Sanofi
  • 10.4. Johnson & Johnson Services, Inc.
  • 10.5. Merck & Co., Inc.
  • 10.6. AbbVie Inc.
  • 10.7. GlaxoSmithKline plc.
  • 10.8. AstraZeneca
  • 10.9. Bristol-Myers Squibb Company
  • 10.10. Amgen Inc.
  • 10.11. Teva Pharmaceutical Industries Ltd.
  • 10.12. Novo Nordisk A/S
  • 10.13. Bayer AG
  • 10.14. Gilead Sciences, Inc
  • 10.15. Eli Lilly and Company
  • 10.16. Allergan
  • 10.17. Takeda Pharmaceutical Company Limited
  • 10.18. Boehringer Ingelheim International GmbH